Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Publishes Final Guidance For Developers Seeking EUAs For Monkeypox Tests, Grants First Approval To Quest

Executive Summary

The US FDA has issued guidance on its current thinking on enforcement policies for EUAs on monkeypox diagnostics, along with recommendations to help developers get their tests approved more quickly.

You may also be interested in...



US FDA Provides Monkeypox Update, Including Testing Protocols

The Centers for Disease Control and Prevention (CDC) is providing the non-variola orthopoxvirus test throughout its public health Laboratory Response Network. The diagnostic is currently the only FDA-cleared test to detect monkeypox.

FDA Publishes Final Guidance On Clinical Decision Support Software, Clarifies What Software Should Be Regulated As Medical Devices

In its final document, the US FDA outlines its interpretations of the four criteria for excluding clinical decision support software from being regulated as medical devices under federal law. Software must meet all four criteria to be excluded.

FDA Updates COVID-19 Test Policy; Shifts Focus From EUAs

As part of a policy revamp, FDA encourages COVID-19 test developers to pursue traditional premarket review pathways rather than emergency use authorizations.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel